{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:53:17Z","timestamp":1790362397275,"version":"4.1.0"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s11604-019-00867-7","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T13:27:05Z","timestamp":1567776425000},"page":"735-749","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Neuroimaging of Alzheimer\u2019s disease: focus on amyloid and tau PET"],"prefix":"10.1007","volume":"37","author":[{"given":"Hiroshi","family":"Matsuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Shigemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,6]]},"reference":[{"key":"867_CR1","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jalz.2016.03.001","volume":"12","author":"Alzheimer's Association","year":"2016","unstructured":"Association Alzheimer's. 2016 Alzheimer's disease facts and figures. Alzheimers Dement. 2016;12:459\u2013509.","journal-title":"Alzheimers Dement"},{"key":"867_CR2","unstructured":"Alzheimer\u2019s Disease International. The state of the art of dementia research: new frontiers. World Alzheimer Report. 2018: the global voice on dementia. 2018. https:\/\/www.alz.co.uk\/research\/world-report-2018 . Accessed 21 Sept 2018."},{"key":"867_CR3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/CEOR.S146788","volume":"10","author":"W Montgomery","year":"2017","unstructured":"Montgomery W, Ueda K, Jorgensen M, Stathis S, Cheng Y, Nakamura T. Epidemiology, associated burden, and current clinical practice for the diagnosis and management of Alzheimer's disease in Japan. Clinicoecon Outcomes Res. 2017;10:13\u201328.","journal-title":"Clinicoecon Outcomes Res"},{"key":"867_CR4","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939\u201344.","journal-title":"Neurology"},{"key":"867_CR5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263\u20139.","journal-title":"Alzheimers Dement"},{"key":"867_CR6","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614\u201329.","journal-title":"Lancet Neurol"},{"key":"867_CR7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","volume":"7","author":"CR Jack Jr","year":"2011","unstructured":"Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:257\u201362.","journal-title":"Alzheimers Dement"},{"key":"867_CR8","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280\u201392.","journal-title":"Alzheimers Dement"},{"key":"867_CR9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","volume":"256","author":"RC Petersen","year":"2004","unstructured":"Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183\u201394.","journal-title":"J Intern Med"},{"key":"867_CR10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0022-510X(02)00159-4","volume":"201","author":"J Meyer","year":"2002","unstructured":"Meyer J, Xu G, Thornby J, Chowdhury M, Quach M. Longitudinal analysis of abnormal domains comprising mild cognitive impairment (MCI) during aging. J Neurol Sci. 2002;201:19\u201325.","journal-title":"J Neurol Sci"},{"key":"867_CR11","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/S0140-6736(06)68542-5","volume":"367","author":"S Gauthier","year":"2006","unstructured":"Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, et al. International psychogeriatric association expert conference on mild cognitive impairment. Lancet. 2006;367:1262\u201370.","journal-title":"Lancet"},{"key":"867_CR12","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270\u20139.","journal-title":"Alzheimers Dement"},{"key":"867_CR13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1479-8301.2007.00197.x","volume":"7","author":"T Ishikawa","year":"2007","unstructured":"Ishikawa T, Ikeda M. Mild cognitive impairment in a population-based epidemiological study. Psychogeriatrics. 2007;7:104\u20138.","journal-title":"Psychogeriatrics"},{"key":"867_CR14","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jalz.2018.03.009","volume":"14","author":"T Iwatsubo","year":"2018","unstructured":"Iwatsubo T, Iwata A, Suzuki K, Ihara R, Arai H, Ishii K, et al. Japanese and North American Alzheimer's disease neuroimaging initiative studies: harmonization for international trials. Alzheimers Dement. 2018;14:1077\u201387.","journal-title":"Alzheimers Dement"},{"key":"867_CR15","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"CR Jack Jr","year":"2016","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87:539\u201347.","journal-title":"Neurology"},{"key":"867_CR16","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1021\/jm030026b","volume":"46","author":"CA Mathis","year":"2003","unstructured":"Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46:2740\u201354.","journal-title":"J Med Chem"},{"key":"867_CR17","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306\u201319.","journal-title":"Ann Neurol"},{"key":"867_CR18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1001\/archneur.64.3.431","volume":"64","author":"BJ Bacskai","year":"2007","unstructured":"Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol. 2007;64:431\u20134.","journal-title":"Arch Neurol"},{"key":"867_CR19","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/brain\/awn016","volume":"131","author":"MD Ikonomovic","year":"2008","unstructured":"Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131:1630\u201345.","journal-title":"Brain"},{"key":"867_CR20","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2967\/jnumed.109.063305","volume":"50","author":"N Nelissen","year":"2009","unstructured":"Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, et al. Phase 1 study of the Pittsburgh Compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med. 2009;50:1251\u20139.","journal-title":"J Nucl Med"},{"key":"867_CR21","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2967\/jnumed.109.069088","volume":"51","author":"DF Wong","year":"2010","unstructured":"Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51:913\u201320.","journal-title":"J Nucl Med"},{"key":"867_CR22","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1474-4422(11)70077-1","volume":"10","author":"H Barthel","year":"2011","unstructured":"Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-\u03b2 PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424\u201335.","journal-title":"Lancet Neurol"},{"key":"867_CR23","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2967\/jnumed.110.076315","volume":"52","author":"CC Rowe","year":"2011","unstructured":"Rowe CC, Villemagne VL. Brain amyloid imaging. J Nucl Med. 2011;52:1733\u201340.","journal-title":"J Nucl Med"},{"key":"867_CR24","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jalz.2018.04.011","volume":"14","author":"BJ Hanseeuw","year":"2018","unstructured":"Hanseeuw BJ, Betensky RA, Mormino EC, Schultz AP, Sepulcre J, Becker JA, et al. PET staging of amyloidosis using striatum. Alzheimers Dement. 2018;14:1281\u201392.","journal-title":"Alzheimers Dement"},{"key":"867_CR25","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2967\/jnumed.108.057984","volume":"50","author":"MT Fodero-Tavoletti","year":"2009","unstructured":"Fodero-Tavoletti MT, Rowe CC, McLean CA, Leone L, Li QX, Masters CL, et al. Characterization of PiB binding to white matter in Alzheimer disease and other dementias. J Nucl Med. 2009;50:198\u2013204.","journal-title":"J Nucl Med"},{"key":"867_CR26","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0969-8051(00)00137-2","volume":"27","author":"J Logan","year":"2000","unstructured":"Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol. 2000;27:661\u201370.","journal-title":"Nucl Med Biol"},{"key":"867_CR27","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1212\/01.wnl.0000228230.26044.a4","volume":"67","author":"MA Mintun","year":"2006","unstructured":"Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446\u201352.","journal-title":"Neurology"},{"key":"867_CR28","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/brain\/awn107","volume":"131","author":"J Koivunen","year":"2008","unstructured":"Koivunen J, Verkkoniemi A, Aalto S, Paetau A, Ahonen JP, Viitanen M, et al. PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. Brain. 2008;131:1845\u201353.","journal-title":"Brain"},{"key":"867_CR29","first-page":"1959","volume":"46","author":"BJ Lopresti","year":"2005","unstructured":"Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46:1959\u201372.","journal-title":"J Nucl Med"},{"key":"867_CR30","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.2967\/jnumed.107.049932","volume":"49","author":"A Mikhno","year":"2008","unstructured":"Mikhno A, Devanand D, Pelton G, Cuasay K, Gunn R, Upton N, et al. Voxel-based analysis of 11C-PIB scans for diagnosing Alzheimer's disease. J Nucl Med. 2008;49:1262\u20139.","journal-title":"J Nucl Med"},{"key":"867_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1\u201315.","journal-title":"Alzheimers Dement"},{"key":"867_CR32","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ana.22248","volume":"69","author":"VL Villemagne","year":"2011","unstructured":"Villemagne VL, Pike KE, Ch\u00e9telat G, Ellis KA, Mulligan RS, Bourgeat P, et al. Longitudinal assessment of A\u03b2 and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69:181\u201392.","journal-title":"Ann Neurol"},{"key":"867_CR33","doi-asserted-by":"crossref","first-page":"e00532","DOI":"10.1002\/brb3.532","volume":"6","author":"K Sasaki","year":"2016","unstructured":"Sasaki K, Maikusa N, Imabayashi E, Yuasa T, Matsuda H. The feasibility of 11C-PIB-PET\/CT for amyloid plaque burden: validation of the effectiveness of CT-based partial volume correction. Brain Behav. 2016;6:e00532.","journal-title":"Brain Behav"},{"key":"867_CR34","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.neuroimage.2016.12.077","volume":"147","author":"G Gonzalez-Escamilla","year":"2017","unstructured":"Gonzalez-Escamilla G, Lange C, Teipel S, Buchert R, Grothe MJ. Alzheimer's disease neuroimaging initiative. PETPVE12: an SPM toolbox for partial volume effects correction in brain PET\u2014application to amyloid imaging with AV45-PET. Neuroimage. 2017;147:669\u201377.","journal-title":"Neuroimage"},{"key":"867_CR35","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1212\/01.wnl.0000219668.47116.e6","volume":"66","author":"DA Bennett","year":"2006","unstructured":"Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66:1837\u201344.","journal-title":"Neurology"},{"key":"867_CR36","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/00005072-199812000-00009","volume":"57","author":"CM Hulette","year":"1998","unstructured":"Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM. Neuropathological and neuropsychological changes in \"normal\" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol. 1998;57:1168\u201374.","journal-title":"J Neuropathol Exp Neurol"},{"key":"867_CR37","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1093\/brain\/awm238","volume":"130","author":"KE Pike","year":"2007","unstructured":"Pike KE, Savage G, Villemagne VL, Ellis KA, Mulligan RS, Bourgeat P, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007;130:2837\u201344.","journal-title":"Brain"},{"key":"867_CR38","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/brain\/awm336","volume":"131","author":"CR Jack Jr","year":"2008","unstructured":"Jack CR Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain. 2008;131:665\u201380.","journal-title":"Brain"},{"key":"867_CR39","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/archneur.65.11.1509","volume":"65","author":"HJ Aizenstein","year":"2008","unstructured":"Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65:1509\u201317.","journal-title":"Arch Neurol"},{"key":"867_CR40","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/brain\/awn320","volume":"132","author":"EC Mormino","year":"2009","unstructured":"Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132:1310\u201323.","journal-title":"Brain"},{"key":"867_CR41","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.neurobiolaging.2010.04.007","volume":"31","author":"CC Rowe","year":"2010","unstructured":"Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275\u201383.","journal-title":"Neurobiol Aging"},{"key":"867_CR42","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.1073\/pnas.0914141107","volume":"107","author":"L Mosconi","year":"2010","unstructured":"Mosconi L, Rinne JO, Tsui WH, Berti V, Li Y, Wang H, Murray J, et al. Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's. Proc Natl Acad Sci USA. 2010;107:5949\u201354.","journal-title":"Proc Natl Acad Sci USA"},{"key":"867_CR43","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.1073\/pnas.0900345106","volume":"106","author":"EM Reiman","year":"2009","unstructured":"Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA. 2009;106:6820\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"867_CR44","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.neuron.2014.01.045","volume":"81","author":"T Kanekiyo","year":"2014","unstructured":"Kanekiyo T, Xu H, Bu G. ApoE and A\u03b2 in Alzheimer\u2019s disease: accidental encounters or partners? Neuron. 2014;81:740\u201354.","journal-title":"Neuron"},{"key":"867_CR45","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.neuron.2009.06.026","volume":"63","author":"J Kim","year":"2009","unstructured":"Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer\u2019s disease. Neuron. 2009;63:287\u2013303.","journal-title":"Neuron"},{"key":"867_CR46","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.1997.03550160069041","volume":"278","author":"LA Farrer","year":"1997","unstructured":"Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA J Am Med Assoc. 1997;278:1349\u201356.","journal-title":"JAMA J Am Med Assoc"},{"key":"867_CR47","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0140-6736(08)61047-8","volume":"372","author":"PH St George-Hyslop","year":"2008","unstructured":"St George-Hyslop PH, Morris JC. Will anti-amyloid therapies work for Alzheimer's disease? Lancet. 2008;372:180\u20132.","journal-title":"Lancet"},{"key":"867_CR48","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1212\/01.wnl.0000261919.22630.ea","volume":"68","author":"CC Rowe","year":"2007","unstructured":"Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68:1718\u201325.","journal-title":"Neurology"},{"key":"867_CR49","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1212\/01.wnl.0000260969.94695.56","volume":"68","author":"NM Kemppainen","year":"2007","unstructured":"Kemppainen NM, Aalto S, Wilson IA, N\u00e5gren K, Helin S, Br\u00fcck A, et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology. 2007;68:1603\u20136.","journal-title":"Neurology"},{"key":"867_CR50","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.neurobiolaging.2007.03.029","volume":"29","author":"A Forsberg","year":"2008","unstructured":"Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29:1456\u201365.","journal-title":"Neurobiol Aging"},{"key":"867_CR51","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/ana.21598","volume":"65","author":"DA Wolk","year":"2009","unstructured":"Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol. 2009;65:557\u201368.","journal-title":"Ann Neurol."},{"key":"867_CR52","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/pcn.12326","volume":"69","author":"Y Omachi","year":"2015","unstructured":"Omachi Y, Ito K, Arima K, Matsuda H, Nakata Y, Sakata M, et al. Clinical impact of (11) C-Pittsburgh Compound-B positron emission tomography carried out in addition to magnetic resonance imaging and single-photon emission computed tomography on the diagnosis of Alzheimer's disease in patients with dementia and mild cognitive impairment. Psychiatry Clin Neurosci. 2015;69:741\u201351.","journal-title":"Psychiatry Clin Neurosci"},{"key":"867_CR53","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2967\/jnumed.106.037762","volume":"48","author":"S Ng","year":"2007","unstructured":"Ng S, Villemagne VL, Berlangieri S, Lee ST, Lee ST, Cherk M, Gong SJ, et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. J Nucl Med. 2007;48:547\u201352.","journal-title":"J Nucl Med"},{"key":"867_CR54","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1212\/01.wnl.0000244749.20056.d4","volume":"68","author":"P Edison","year":"2007","unstructured":"Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology. 2007;68:501\u20138.","journal-title":"Neurology"},{"key":"867_CR55","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jalz.2012.07.003","volume":"9","author":"R Ossenkoppele","year":"2013","unstructured":"Ossenkoppele R, Prins ND, Pijnenburg YA, Lemstra AW, van der Flier WM, Adriaanse SF, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement. 2013;9:414\u201321.","journal-title":"Alzheimers Dement"},{"key":"867_CR56","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00259-015-3228-x","volume":"43","author":"E Morris","year":"2016","unstructured":"Morris E, Chalkidou A, Hammers A, Peacock J, Summers J, Keevil S. Diagnostic accuracy of 18F amyloid PET tracers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2016;43:374\u201385.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"867_CR57","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/archneur.55.3.326","volume":"55","author":"L Berg","year":"1998","unstructured":"Berg L, McKeel DW Jr, Miller JP, Storandt M, Rubin EH, Morris JC, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol. 1998;55:326\u201335.","journal-title":"Arch Neurol"},{"key":"867_CR58","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/archneur.65.10.noc80013","volume":"65","author":"V Leinonen","year":"2008","unstructured":"Leinonen V, Alafuzoff I, Aalto S, Suotunen T, Savolainen S, N\u00e5gren K, et al. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol. 2008;65:1304\u20139.","journal-title":"Arch Neurol"},{"key":"867_CR59","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/archneurol.2009.279","volume":"66","author":"NJ Cairns","year":"2009","unstructured":"Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah AR, et al. Absence of Pittsburgh Compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and CSF markers of Alzheimer disease: a case report. Arch Neurol. 2009;66:1557\u2013622.","journal-title":"Arch Neurol"},{"key":"867_CR60","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.20730","volume":"59","author":"AM Fagan","year":"2006","unstructured":"Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and CSF Abeta42 in humans. Ann Neurol. 2006;59:512\u20139.","journal-title":"Ann Neurol"},{"key":"867_CR61","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/ana.21559","volume":"65","author":"AM Fagan","year":"2009","unstructured":"Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, et al. Decreased CSF Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65:176\u201383.","journal-title":"Ann Neurol"},{"key":"867_CR62","doi-asserted-by":"crossref","first-page":"6174","DOI":"10.1523\/JNEUROSCI.0730-07.2007","volume":"27","author":"WE Klunk","year":"2007","unstructured":"Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007;27:6174\u201384.","journal-title":"J Neurosci"},{"key":"867_CR63","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/archneurol.2009.285","volume":"66","author":"VL Villemagne","year":"2009","unstructured":"Villemagne VL, Ataka S, Mizuno T, Brooks WS, Wada Y, Kondo M, et al. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol. 2009;66:1537\u201344.","journal-title":"Arch Neurol"},{"key":"867_CR64","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jalz.2015.07.490","volume":"12","author":"T Annus","year":"2016","unstructured":"Annus T, Wilson LR, Hong YT, Acosta-Cabronero J, Fryer TD, Cardenas-Blanco A, et al. The pattern of amyloid accumulation in the brains of adults with Down syndrome. Alzheimers Dement. 2016;12:538\u201345.","journal-title":"Alzheimers Dement"},{"key":"867_CR65","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nrneurol.2015.251","volume":"12","author":"CR Jack Jr","year":"2016","unstructured":"Jack CR Jr, Knopman DS, Ch\u00e9telat G, Dickson D, Fagan AM, Frisoni GB, et al. Suspected non-Alzheimer disease pathophysiology\u2014concept and controversy. Nat Rev Neurol. 2016;12:117\u201324.","journal-title":"Nat Rev Neurol"},{"key":"867_CR66","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S1474-4422(16)30125-9","volume":"15","author":"SC Burnham","year":"2016","unstructured":"Burnham SC, Bourgeat P, Dor\u00e9 V, Savage G, Brown B, Laws S, et al. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study. Lancet Neurol. 2016;15:1044\u201353.","journal-title":"Lancet Neurol"},{"key":"867_CR67","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaneurol.2016.5349","volume":"74","author":"S Schreiber","year":"2017","unstructured":"Schreiber S, Schreiber F, Lockhart SN, Horng A, Bejanin A, Landau SM, et al. Alzheimer disease signature neurodegeneration and APOE genotype in mild cognitive impairment with suspected non-Alzheimer disease pathophysiology. JAMA Neurol. 2017;74:650\u20139.","journal-title":"JAMA Neurol"},{"key":"867_CR68","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2967\/jnumed.114.150045","volume":"56","author":"K Ishibashi","year":"2015","unstructured":"Ishibashi K, Onishi A, Fujiwara Y, Ishiwata K, Ishii K. Relationship between Alzheimer disease-like pattern of 18F-FDG and fasting plasma glucoselevels in cognitively normal volunteers. J Nucl Med. 2015;56:229\u201333.","journal-title":"J Nucl Med"},{"key":"867_CR69","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/brain\/awz099","volume":"142","author":"PT Nelson","year":"2019","unstructured":"Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142:1503\u201327.","journal-title":"Brain"},{"key":"867_CR70","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2019.2000","volume":"321","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321:1286\u201394.","journal-title":"JAMA"},{"key":"867_CR71","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1001\/jama.2019.1998","volume":"321","author":"CR Jack Jr","year":"2019","unstructured":"Jack CR Jr, Petersen RC. Amyloid PET and changes in clinical management for patients with cognitive impairment. JAMA. 2019;321:1258\u201360.","journal-title":"JAMA"},{"key":"867_CR72","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1007\/s00259-019-04297-5","volume":"46","author":"A Leuzy","year":"2019","unstructured":"Leuzy A, Savitcheva I, Chiotis K, Lilja J, Andersen P, Bogdanovic N, et al. Clinical impact of [18F]flutemetamol PET among memory clinic patients with an unclear diagnosis. Eur J Nucl Med Mol Imaging. 2019;46:1276\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"867_CR73","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00019442-200201000-00004","volume":"10","author":"K Shoghi-Jadid","year":"2002","unstructured":"Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry. 2002;10:24\u201335.","journal-title":"Am J Geriatr Psychiatry"},{"key":"867_CR74","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.neuron.2013.07.037","volume":"79","author":"M Maruyama","year":"2013","unstructured":"Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79:1094\u2013108.","journal-title":"Neuron"},{"key":"867_CR75","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.nucmedbio.2015.08.006","volume":"42","author":"H Hashimoto","year":"2015","unstructured":"Hashimoto H, Kawamura K, Takei M, Igarashi N, Fujishiro T, Shiomi S, et al. Identification of a major radiometabolite of [11C]PBB3. Nucl Med Biol. 2015;42:905\u201310.","journal-title":"Nucl Med Biol"},{"key":"867_CR76","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.2967\/jnumed.112.117341","volume":"54","author":"N Okamura","year":"2013","unstructured":"Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M, et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med. 2013;54:1420\u20137.","journal-title":"J Nucl Med"},{"key":"867_CR77","doi-asserted-by":"crossref","first-page":"208","DOI":"10.2967\/jnumed.115.164848","volume":"57","author":"R Harada","year":"2016","unstructured":"Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, et al. 18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease. J Nucl Med. 2016;57:208\u201314.","journal-title":"J Nucl Med"},{"key":"867_CR78","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13195-017-0253-y","volume":"9","author":"KP Ng","year":"2017","unstructured":"Ng KP, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MS, Shin M, et al. Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. Alzheimers Res Ther. 2017;9:25.","journal-title":"Alzheimers Res Ther"},{"key":"867_CR79","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/ana.24517","volume":"78","author":"M Marqui\u00e9","year":"2015","unstructured":"Marqui\u00e9 M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78:787\u2013800.","journal-title":"Ann Neurol"},{"key":"867_CR80","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jalz.2016.01.003","volume":"12","author":"K Sander","year":"2016","unstructured":"Sander K, Lashley T, Gami P, Gendron T, Lythgoe MF, Rohrer JD, et al. Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias. Alzheimers Dement. 2016;12:1116\u201324.","journal-title":"Alzheimers Dement"},{"key":"867_CR81","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40478-016-0315-6","volume":"4","author":"VJ Lowe","year":"2016","unstructured":"Lowe VJ, Curran G, Fang P, Liesinger AM, Josephs KA, Parisi JE, et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun. 2016;4:58.","journal-title":"Acta Neuropathol Commun"},{"key":"867_CR82","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s40478-017-0482-0","volume":"5","author":"M Marqui\u00e9","year":"2017","unstructured":"Marqui\u00e9 M, Verwer EE, Meltzer AC, Kim SJW, Ag\u00fcero C, Gonzalez J, et al. Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's case. Acta Neuropathol Commun. 2017;5:75.","journal-title":"Acta Neuropathol Commun"},{"key":"867_CR83","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3233\/JAD-170840","volume":"62","author":"CM Lee","year":"2018","unstructured":"Lee CM, Jacobs HIL, Marqui\u00e9 M, Becker JA, Andrea NV, Jin DS, et al. 18F-Flortaucipir binding in choroid plexus: related to race and hippocampus signal. J Alzheimers Dis. 2018;62:1691\u2013702.","journal-title":"J Alzheimers Dis"},{"key":"867_CR84","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.expneurol.2004.06.011","volume":"190","author":"MD Ikonomovic","year":"2004","unstructured":"Ikonomovic MD, Uryu K, Abrahamson EE, Ciallella JR, Trojanowski JQ, Lee VM, et al. Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury. Exp Neurol. 2004;190:192\u2013203.","journal-title":"Exp Neurol"},{"key":"867_CR85","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2967\/jnumed.117.195248","volume":"59","author":"JY Choi","year":"2018","unstructured":"Choi JY, Cho H, Ahn SJ, Lee JH, Ryu YH, Lee MS, et al. Off-target 18F-AV-1451 binding in the basal ganglia correlates with age-related iron accumulation. J Nucl Med. 2018;59:117\u201320.","journal-title":"J Nucl Med"},{"key":"867_CR86","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mds.27271","volume":"33","author":"C Vermeiren","year":"2018","unstructured":"Vermeiren C, Motte P, Viot D, Mairet-Coello G, Courade JP, Citron M, et al. The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases. Mov Disord. 2018;33:273\u201381.","journal-title":"Mov Disord"},{"key":"867_CR87","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11307-017-1143-1","volume":"20","author":"AK Hansen","year":"2018","unstructured":"Hansen AK, Brooks DJ, Borghammer P. MAO-B Inhibitors do not block in vivo Flortaucipir ([18F]-AV-1451) binding. Mol Imaging Biol. 2018;20:356\u201360.","journal-title":"Mol Imaging Biol"},{"key":"867_CR88","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2967\/jnumed.117.196741","volume":"59","author":"M Honer","year":"2018","unstructured":"Honer M, Gobbi L, Knust H, Kuwabara H, Muri D, Koerner M, et al. Preclinical evaluation of 18F-RO6958948, 11C-RO6931643, and 11C-RO6924963 as novel PET radiotracers for imaging tau aggregates in Alzheimer disease. J Nucl Med. 2018;59:675\u201381.","journal-title":"J Nucl Med"},{"key":"867_CR89","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.2967\/jnumed.118.214437","volume":"59","author":"H Kuwabara","year":"2018","unstructured":"Kuwabara H, Comley RA, Borroni E, Honer M, Kitmiller K, Roberts J, et al. Evaluation of 18F-RO-948 PET for quantitative assessment of tau accumulation in the human brain. J Nucl Med. 2018;59:1877\u201384.","journal-title":"J Nucl Med"},{"key":"867_CR90","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.2967\/jnumed.115.171678","volume":"57","author":"ED Hostetler","year":"2016","unstructured":"Hostetler ED, Walji AM, Zeng Z, Miller P, Bennacef I, Salinas C, et al. Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J Nucl Med. 2016;57:1599\u2013606.","journal-title":"J Nucl Med"},{"key":"867_CR91","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13195-018-0402-y","volume":"10","author":"TA Pascoal","year":"2018","unstructured":"Pascoal TA, Shin M, Kang MS, Chamoun M, Chartrand D, Mathotaarachchi S, et al. In vivo quantification of neurofibrillary tangles with [18F]MK-6240. Alzheimers Res Ther. 2018;10:74.","journal-title":"Alzheimers Res Ther"},{"key":"867_CR92","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2967\/jnumed.118.209650","volume":"60","author":"TJ Betthauser","year":"2019","unstructured":"Betthauser TJ, Cody KA, Zammit MD, Murali D, Converse AK, Barnhart TE, et al. In vivo characterization and quantification of neurofibrillary tau PET radioligand 18F-MK-6240 in humans from Alzheimer disease dementia to young controls. J Nucl Med. 2019;60:93\u20139.","journal-title":"J Nucl Med"},{"key":"867_CR93","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2967\/jnumed.118.208215","volume":"60","author":"TG Lohith","year":"2019","unstructured":"Lohith TG, Bennacef I, Vandenberghe R, Vandenbulcke M, Salinas CA, Declercq R, et al. Brain imaging of Alzheimer dementia patients and elderly controls with 18F-MK-6240, a PET tracer targeting neurofibrillary tangles. J Nucl Med. 2019;60:107\u201314.","journal-title":"J Nucl Med"},{"key":"867_CR94","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04399-0","author":"S Sanabria Boh\u00f3rquez","year":"2019","unstructured":"Sanabria Boh\u00f3rquez S, Marik J, Ogasawara A, Tinianow JN, Gill HS, Barret O, et al. [18F]GTP1 (Genentech Tau Probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2019. https:\/\/doi.org\/10.1007\/s00259-019-04399-0 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"867_CR95","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04397-2","author":"H Kroth","year":"2019","unstructured":"Kroth H, Oden F, Molette J, Schieferstein H, Capotosti F, Mueller A, et al. Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer's disease and other tauopathies. Eur J Nucl Med Mol Imaging. 2019. https:\/\/doi.org\/10.1007\/s00259-019-04397-2 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"867_CR96","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.neuroimage.2017.05.058","volume":"157","author":"A Maass","year":"2017","unstructured":"Maass A, Landau S, Baker SL, Horng A, Lockhart SN, La Joie R, et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. Neuroimage. 2017;157:448\u201363.","journal-title":"Neuroimage"},{"key":"867_CR97","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ana.25395","volume":"85","author":"RA Sperling","year":"2019","unstructured":"Sperling RA, Mormino EC, Schultz AP, Betensky RA, Papp KV, Amariglio RE, et al. The impact of amyloid-beta and tau on prospective cognitive decline in older individuals. Ann Neurol. 2019;85:181\u201393.","journal-title":"Ann Neurol"},{"key":"867_CR98","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1007\/s00259-016-3363-z","volume":"43","author":"K Chiotis","year":"2016","unstructured":"Chiotis K, Saint-Aubert L, Savitcheva I, Jelic V, Andersen P, Jonasson M, et al. Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm. Eur J Nucl Med Mol Imaging. 2016;43:1686\u201399.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"867_CR99","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1212\/WNL.0000000000002892","volume":"87","author":"H Cho","year":"2016","unstructured":"Cho H, Choi JY, Hwang MS, Lee JH, Kim YJ, Lee HM, et al. Tau PET in Alzheimer disease and mild cognitive impairment. Neurology. 2016;87:375\u201383.","journal-title":"Neurology"},{"key":"867_CR100","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ana.24546","volume":"79","author":"KA Johnson","year":"2016","unstructured":"Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79:110\u20139.","journal-title":"Ann Neurol"},{"key":"867_CR101","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ana.24711","volume":"80","author":"H Cho","year":"2016","unstructured":"Cho H, Choi JY, Hwang MS, Kim YJ, Lee HM, Lee HS, et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol. 2016;80:247\u201358.","journal-title":"Ann Neurol"},{"key":"867_CR102","first-page":"748","volume":"140","author":"MJ Pontecorvo","year":"2017","unstructured":"Pontecorvo MJ, Devous MD Sr, Navitsky M, Lu M, Salloway S, Schaerf FW, et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain. 2017;140:748\u201363.","journal-title":"Brain"},{"key":"867_CR103","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13195-018-0403-x","volume":"10","author":"N Mattsson","year":"2018","unstructured":"Mattsson N, Ossenkoppele R, Smith R, Strandberg O, Ohlsson T, J\u00f6gi J, et al. Greater tau load and reduced cortical thickness in APOE \u03b54-negative Alzheimer's disease: a cohort study. Alzheimers Res Ther. 2018;10:77.","journal-title":"Alzheimers Res Ther"},{"key":"867_CR104","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele R, Schonhaut DR, Sch\u00f6ll M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain. 2016;139:1551\u2013677.","journal-title":"Brain"},{"key":"867_CR105","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00401-014-1349-0","volume":"128","author":"JF Crary","year":"2014","unstructured":"Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128:755\u201366.","journal-title":"Acta Neuropathol"},{"key":"867_CR106","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13550-019-0552-3","volume":"9","author":"Y Shigemoto","year":"2019","unstructured":"Shigemoto Y, Sone D, Ota M, Maikusa N, Ogawa M, Okita K, et al. Voxel-based comparison of 18F-THK5351 accumulation and gray matter volume in the brain of cognitively normal older adults. EJNMMI Res 2019;9:81.","journal-title":"EJNMMI Res"},{"key":"867_CR107","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jalz.2018.07.215","volume":"15","author":"WR Bell","year":"2019","unstructured":"Bell WR, An Y, Kageyama Y, English C, Rudow GL, Pletnikova O, et al. Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer's disease. Alzheimers Dement. 2019;15:8\u201316.","journal-title":"Alzheimers Dement"},{"key":"867_CR108","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.dadm.2017.07.001","volume":"9","author":"D Sone","year":"2017","unstructured":"Sone D, Imabayashi E, Maikusa N, Okamura N, Furumoto S, Kudo Y, et al. Regional tau deposition and subregion atrophy of medial temporal structures in early Alzheimer's disease: a combined positron emission tomography\/magnetic resonance imaging study. Alzheimers Dement (Amst). 2017;9:35\u201340.","journal-title":"Alzheimers Dement (Amst)"},{"key":"867_CR109","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3389\/fnagi.2018.00223","volume":"10","author":"Y Shigemoto","year":"2018","unstructured":"Shigemoto Y, Sone D, Imabayashi E, Maikusa N, Okamura N, Furumoto S, et al. Dissociation of tau deposits and brain atrophy in early Alzheimer\u2019s disease: a combined positron emission tomography\/magnetic resonance imaging study. Front Aging Neurosci. 2018;10:223.","journal-title":"Front Aging Neurosci"},{"key":"867_CR110","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/ana.25406","volume":"85","author":"TM Harrison","year":"2019","unstructured":"Harrison TM, La Joie R, Maass A, Baker SL, Swinnerton K, Fenton L, et al. Longitudinal tau accumulation and atrophy in aging and alzheimer disease. Ann Neurol. 2019;85:229\u201340.","journal-title":"Ann Neurol"},{"key":"867_CR111","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fnins.2017.00167","volume":"11","author":"O Hansson","year":"2017","unstructured":"Hansson O, Grothe MJ, Strandberg TO, Ohlsson T, H\u00e4gerstr\u00f6m D, J\u00f6gi J, et al. Tau pathology distribution in Alzheimer's disease corresponds differentially to cognition-relevant functional brain networks. Front Neurosci. 2017;11:167.","journal-title":"Front Neurosci"},{"key":"867_CR112","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1523\/JNEUROSCI.3263-16.2017","volume":"37","author":"AP Schultz","year":"2017","unstructured":"Schultz AP, Chhatwal JP, Hedden T, Mormino EC, Hanseeuw BJ, Sepulcre J, et al. Phases of hyperconnectivity and hypoconnectivity in the default mode and salience networks track with amyloid and tau in clinically normal individuals. J Neurosci. 2017;37:4323\u201331.","journal-title":"J Neurosci"},{"key":"867_CR113","doi-asserted-by":"crossref","first-page":"e01145","DOI":"10.1002\/brb3.1145","volume":"8","author":"Y Shigemoto","year":"2018","unstructured":"Shigemoto Y, Sone D, Maikusa N, Okamura N, Furumoto S, Kudo Y, et al. Association of deposition of tau and amyloid-\u03b2 proteins with structural connectivity changes in cognitively normal older adults and Alzheimer\u2019s disease spectrum patients. Brain Behav. 2018;8:e01145.","journal-title":"Brain Behav"},{"key":"867_CR114","doi-asserted-by":"crossref","first-page":"228fs13","DOI":"10.1126\/scitranslmed.3007941","volume":"6","author":"RA Sperling","year":"2014","unstructured":"Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6:228fs13.","journal-title":"Sci Transl Med."},{"key":"867_CR115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/alzrt59","volume":"3","author":"RJ Bateman","year":"2011","unstructured":"Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther. 2011;3:1.","journal-title":"Alzheimers Res Ther"},{"key":"867_CR116","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nrneurol.2013.107","volume":"9","author":"JB Langbaum","year":"2013","unstructured":"Langbaum JB, Fleisher AS, Chen K, Ayutyanont N, Lopera F, Quiroz YT, et al. Ushering in the study and treatment of preclinical Alzheimer disease. Nat Rev Neurol. 2013;9:371\u201381.","journal-title":"Nat Rev Neurol"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-019-00867-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11604-019-00867-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-019-00867-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T23:01:50Z","timestamp":1695164510000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11604-019-00867-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,6]]},"references-count":116,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["867"],"URL":"https:\/\/doi.org\/10.1007\/s11604-019-00867-7","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,6]]},"assertion":[{"value":"23 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflict of interest to disclose with respect to this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}